Dr Jérémie Nsengimana
| Identification of genes associated with testicular germ cell tumor susceptibility through a transcriptome-wide association study | 2025 |
|
Dr Jérémie Nsengimana
| Immune subtyping of melanoma whole slide images using multiple instance learning | 2024 |
|
Dr Abi Gault
Dr Linda Hogarth
Dr Kristian Williams
Professor Alastair Greystoke
Professor Neil Rajan
et al. | Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort study | 2024 |
|
Dr Jérémie Nsengimana
| Multilevel graph representations of melanoma whole slide images for identifying immune subgroups | 2024 |
|
Dr Jérémie Nsengimana
| Peroxiredonixin-2 represses NRAS-mutated melanoma cells invasion by modulating EMT markers | 2024 |
|
Dr Jérémie Nsengimana
Dr Theophile Bigirumurame
| Systemic Inflammation, the peripheral blood transcriptome and primary melanoma | 2024 |
|
Dr Svetlana Cherlin
Dr Theophile Bigirumurame
Dr Michael Grayling
Dr Jérémie Nsengimana
Luke Ouma
et al. | Utilising high-dimensional data in randomised clinical trials: a review of methods and practice | 2024 |
|
Dr Jérémie Nsengimana
| GABA regulates electrical activity and tumour initiation in melanoma | 2023 |
|
Dr Jérémie Nsengimana
| Identifying the Transcriptional Drivers of Metastasis Embedded within Localized Melanoma | 2023 |
|
Dr Jérémie Nsengimana
| ROR2 promotes epithelial to mesenchymal transition by hyperactivating ERK in melanoma | 2023 |
|
Dr Jérémie Nsengimana
| Association Study between Polymorphisms in DNA Methylation-Related Genes and Testicular Germ Cell Tumor Risk | 2022 |
|
Dr Jérémie Nsengimana
| Defining novel causal SNPs and linked phenotypes at melanoma-associated loci | 2022 |
|
Dr Jérémie Nsengimana
| Genes regulated by DNA methylation are involved in distinct phenotypes during melanoma progression and are prognostic factors for patients | 2022 |
|
Dr Jérémie Nsengimana
| Ulcerated melanoma: Systems biology evidence of inflammatory imbalance towards pro-tumourigenicity | 2022 |
|
Dr Jérémie Nsengimana
| Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formation | 2021 |
|
Dr Jérémie Nsengimana
| Identification of 22 susceptibility loci associated with testicular germ cell tumors | 2021 |
|
Dr Jérémie Nsengimana
| Inherited duplications of PPP2R3B predispose to nevi and melanoma via C21orf91-driven proliferative phenotype | 2021 |
|
Dr Jérémie Nsengimana
| MX2 mediates establishment of interferon response profile, regulates XAF1, and can sensitize melanoma cell to targeted therapy | 2021 |
|
Dr Jérémie Nsengimana
| ROR2 has a protective role in melanoma by inhibiting Akt activity, cell cycle progression and proliferation | 2021 |
|
Dr Jérémie Nsengimana
| SFPQ promotes an oncogenic transcriptomic state in melanoma | 2021 |
|
Dr Jérémie Nsengimana
| The role of CAF derived exosomal microRNAs in the tumour microenvironment of melanoma | 2021 |
|
Dr Jérémie Nsengimana
| Transcriptional signatures underlying dynamic phenotypic switching and novel disease biomarkers in a linear cellular model of melanoma progression | 2021 |
|
Dr Jérémie Nsengimana
| Tumour gene expression signature in primary melanoma predicts long-term outcomes | 2021 |
|
Dr Helen Close
Dr Jérémie Nsengimana
| Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma | 2020 |
|
Dr Jérémie Nsengimana
| Factors affecting sentinel node metastasis in thin cutaneous melanomas: development and external validation of a predictive nomogram | 2020 |
|
Dr Jérémie Nsengimana
| Gene co-expression and histone modification signatures are associated with melanoma progression, epithelial-to-mesenchimal transition and metastasis | 2020 |
|
Dr Jérémie Nsengimana
| MX 2 is a novel regulator of cell cycle in melanoma cells | 2020 |
|
Dr Jérémie Nsengimana
| Study of the female sex survival advantage in melanoma- a focus on X-linked epigenetic regulators and immune responses in two cohorts | 2020 |
|
Dr Jérémie Nsengimana
Batool Shannan
| Application of circulating cell-free tumor DNA profiles for therapeutic monitoring and outcome prediction in genetically heterogeneous metastatic melanoma | 2019 |
|
Dr Jérémie Nsengimana
| Genetic and environmental determinants of immune response to cutaneous melanoma | 2019 |
|
Dr Jérémie Nsengimana
| High-Resolution Copy Number Patterns From Clinically Relevant FFPE Material | 2019 |
|
Dr Jérémie Nsengimana
| Transcriptomic Analysis Reveals Prognostic Molecular Signatures of Stage I Melanoma | 2019 |
|
Dr Jérémie Nsengimana
| Vitamin D–VDR signaling inhibits Wnt/b-catenin–mediated melanoma progression and promotes antitumor immunity | 2019 |
|
Dr Jérémie Nsengimana
| Comparative genomics reveals that loss of lunatic fringe (LFNG) promotes melanoma metastasis | 2018 |
|
Dr Jérémie Nsengimana
| Large-scale Sequencing of Testicular Germ Cell Tumour (TGCT) Cases Excludes Major TGCT Predisposition Gene | 2018 |
|
Dr Jérémie Nsengimana
| β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas | 2018 |
|
Dr Jérémie Nsengimana
| A screen for combination therapies in BRAF/NRAS wild type melanoma identifies nilotinib plus MEK inhibitor as a synergistic combination | 2017 |
|
Dr Jérémie Nsengimana
| Design considerations for genetic linkage and association studies | 2017 |
|
Dr Jérémie Nsengimana
| Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148 | 2017 |
|
Dr Jérémie Nsengimana
| Genomic expression differences between cutaneous cells from red hair color individuals and black hair color individuals based on bioinformatic analysis | 2017 |
|
Dr Jérémie Nsengimana
| Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor | 2017 |
|
Dr Jérémie Nsengimana
| Identification of a gene signature for discriminating metastatic from primary melanoma using a molecular interaction network approach | 2017 |
|
Dr Jérémie Nsengimana
| Consensus of Melanoma Gene Expression Subtypes Converges on Biological Entities | 2016 |
|
Amy Lloyd
Dr Jérémie Nsengimana
| Identification of four new susceptibility loci for testicular germ cell tumour | 2015 |
|
Dr Jérémie Nsengimana
| Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort | 2015 |
|
Dr Jérémie Nsengimana
| Multi-stage genome-wide association study identifies new susceptibility locus for testicular germ cell tumour on chromosome 3q25 | 2015 |
|
Dr Jérémie Nsengimana
| Prognostic Significance of Promoter Hypermethylation and Diminished Gene Expression of SYNPO2 in Melanoma | 2015 |
|
Dr Jérémie Nsengimana
| The clinicopathological and gene expression patterns associated with ulceration of primary melanoma | 2015 |
|
Dr Jérémie Nsengimana
| Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer | 2014 |
|
Dr Jérémie Nsengimana
| Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy | 2014 |
|
Dr Jérémie Nsengimana
| Renin–angiotensin system genes and coronary artery calcification | 2007 |
|
